Search Results - "Tessa L. Holyoake"

The chronic myeloid leukemia stem cell: stemming the tide of persistence by Holyoake, Tessa L., Vetrie, David

“…Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem…”
Get full text

Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells by Kuntz, Elodie M, Baquero, Pablo, Michie, Alison M, Dunn, Karen, Tardito, Saverio, Holyoake, Tessa L, Helgason, G Vignir, Gottlieb, Eyal

“…Treatment with tyrosine kinase inhibitors results in a survival benefit in patients with chronic myeloid leukemia (CML). However, relapse due to persistent…”
Get full text

Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib by Li, Ling, Wang, Lisheng, Li, Liang, Wang, Zhiqiang, Ho, Yinwei, McDonald, Tinisha, Holyoake, Tessa L., Chen, WenYong, Bhatia, Ravi

“…BCR-ABL tyrosine kinase inhibitors (TKI) fail to eliminate quiescent leukemia stem cells (LSC) in chronic myelogenous leukemia (CML). Thus, strategies…”
Get full text

Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia by Zhang, Bin, Ho, Yin Wei, Huang, Qin, Maeda, Takahiro, Lin, Allen, Lee, Sung-uk, Hair, Alan, Holyoake, Tessa L., Huettner, Claudia, Bhatia, Ravi

“…We characterized leukemia stem cells (LSC) in chronic phase chronic myelogenous leukemia (CML) using a transgenic mouse model. LSC were restricted to cells…”
Get full text

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells by Zhang, Bin, Chu, Su, Agarwal, Puneet, Campbell, Victoria L., Hopcroft, Lisa, Jørgensen, Heather G., Lin, Allen, Gaal, Karl, Holyoake, Tessa L., Bhatia, Ravi

“…Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at…”
Get full text

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia by Herrmann, Harald, Sadovnik, Irina, Cerny-Reiterer, Sabine, Rülicke, Thomas, Stefanzl, Gabriele, Willmann, Michael, Hoermann, Gregor, Bilban, Martin, Blatt, Katharina, Herndlhofer, Susanne, Mayerhofer, Matthias, Streubel, Berthold, Sperr, Wolfgang R., Holyoake, Tessa L., Mannhalter, Christine, Valent, Peter

“…Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are…”
Get full text

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells by Abraham, Sheela A., Hopcroft, Lisa E. M., Carrick, Emma, Drotar, Mark E., Dunn, Karen, Williamson, Andrew J. K., Korfi, Koorosh, Baquero, Pablo, Park, Laura E., Scott, Mary T., Pellicano, Francesca, Pierce, Andrew, Copland, Mhairi, Nourse, Craig, Grimmond, Sean M., Vetrie, David, Whetton, Anthony D., Holyoake, Tessa L.

“…Chronic myeloid leukaemia (CML) arises after transformation of a haemopoietic stem cell (HSC) by the protein-tyrosine kinase BCR–ABL. Direct inhibition of…”
Get full text

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy by Kinstrie, Ross, Horne, Gillian A., Morrison, Heather, Irvine, David, Munje, Chinmay, Castañeda, Eduardo Gómez, Moka, Hothri A., Dunn, Karen, Cassels, Jennifer E., Parry, Narissa, Clarke, Cassie J., Scott, Mary T., Clark, Richard E., Holyoake, Tessa L., Wheadon, Helen, Copland, Mhairi

“…The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the…”
Get full text

Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia by Zhang, Bin, Nguyen, Le Xuan Truong, Li, Ling, Zhao, Dandan, Kumar, Bijender, Wu, Herman, Lin, Allen, Pellicano, Francesca, Hopcroft, Lisa, Su, Yu-Lin, Copland, Mhairi, Holyoake, Tessa L, Kuo, Calvin J, Bhatia, Ravi, Snyder, David S, Ali, Haris, Stein, Anthony S, Brewer, Casey, Wang, Huafeng, McDonald, Tinisha, Swiderski, Piotr, Troadec, Estelle, Chen, Ching-Cheng, Dorrance, Adrienne, Pullarkat, Vinod, Yuan, Yate-Ching, Perrotti, Danilo, Carlesso, Nadia, Forman, Stephen J, Kortylewski, Marcin, Kuo, Ya-Huei, Marcucci, Guido

“…In chronic myelogenous leukemia, leukemia stem cell function requires a microRNA that is provided by bone marrow endothelial cells. Leukemia stem cells (LSCs)…”
Get full text

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells by Neviani, Paolo, Harb, Jason G, Oaks, Joshua J, Santhanam, Ramasamy, Walker, Christopher J, Ellis, Justin J, Ferenchak, Gregory, Dorrance, Adrienne M, Paisie, Carolyn A, Eiring, Anna M, Ma, Yihui, Mao, Hsiaoyin C, Zhang, Bin, Wunderlich, Mark, May, Philippa C, Sun, Chaode, Saddoughi, Sahar A, Bielawski, Jacek, Blum, William, Klisovic, Rebecca B, Solt, Janelle A, Byrd, John C, Volinia, Stefano, Cortes, Jorge, Huettner, Claudia S, Koschmieder, Steffen, Holyoake, Tessa L, Devine, Steven, Caligiuri, Michael A, Croce, Carlo M, Garzon, Ramiro, Ogretmen, Besim, Arlinghaus, Ralph B, Chen, Ching-Shih, Bittman, Robert, Hokland, Peter, Roy, Denis-Claude, Milojkovic, Dragana, Apperley, Jane, Goldman, John M, Reid, Alistair, Mulloy, James C, Bhatia, Ravi, Marcucci, Guido, Perrotti, Danilo

“…The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) depends on the requirement for BCR-ABL1 kinase activity in CML…”
Get full text

Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition by Scott, Mary T, Korfi, Koorosh, Saffrey, Peter, Hopcroft, Lisa E M, Kinstrie, Ross, Pellicano, Francesca, Guenther, Carla, Gallipoli, Paolo, Cruz, Michelle, Dunn, Karen, Jorgensen, Heather G, Cassels, Jennifer E, Hamilton, Ashley, Crossan, Andrew, Sinclair, Amy, Holyoake, Tessa L, Vetrie, David

“…A major obstacle to curing chronic myeloid leukemia (CML) is residual disease maintained by tyrosine kinase inhibitor (TKI)-persistent leukemic stem cells…”
Get more information

CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression by Tarafdar, Anuradha, Hopcroft, Lisa E.M., Gallipoli, Paolo, Pellicano, Francesca, Cassels, Jennifer, Hair, Alan, Korfi, Koorosh, Jørgensen, Heather G., Vetrie, David, Holyoake, Tessa L., Michie, Alison M.

“…Targeting the fusion oncoprotein BCR-ABL with tyrosine kinase inhibitors has significantly affected chronic myeloid leukemia (CML) treatment, transforming the…”
Get full text

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells by Bolton-Gillespie, Elisabeth, Schemionek, Mirle, Klein, Hans-Ulrich, Flis, Sylwia, Hoser, Grazyna, Lange, Thoralf, Nieborowska-Skorska, Margaret, Maier, Jacqueline, Kerstiens, Linda, Koptyra, Mateusz, Müller, Martin C., Modi, Hardik, Stoklosa, Tomasz, Seferynska, Ilona, Bhatia, Ravi, Holyoake, Tessa L., Koschmieder, Steffen, Skorski, Tomasz

“…Genomic instability is a hallmark of chronic myeloid leukemia in chronic phase (CML-CP) resulting in BCR-ABL1 mutations encoding resistance to tyrosine kinase…”
Get full text

The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors by Pellicano, Francesca, Scott, Mary T., Helgason, G. Vignir, Hopcroft, Lisa E. M., Allan, Elaine K., Aspinall‐O'Dea, Mark, Copland, Mhairi, Pierce, Andrew, Huntly, Brian J. P., Whetton, Anthony D., Holyoake, Tessa L.

“…Chronic myeloid leukemia (CML) is initiated and maintained by the tyrosine kinase BCR‐ABL which activates a number of signal transduction pathways, including…”
Get full text

Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606 by Konig, Heiko, Holyoake, Tessa L., Bhatia, Ravi

“…Imatinib mesylate (imatinib) is highly effective in the treatment of chronic myeloid leukemia (CML) but is less effective in eliminating CML stem cells. We…”
Get full text

Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors by Nieborowska-Skorska, Margaret, Kopinski, Piotr K., Ray, Regina, Hoser, Grazyna, Ngaba, Danielle, Flis, Sylwia, Cramer, Kimberly, Reddy, Mamatha M., Koptyra, Mateusz, Penserga, Tyrone, Glodkowska-Mrowka, Eliza, Bolton, Elisabeth, Holyoake, Tessa L., Eaves, Connie J., Cerny-Reiterer, Sabine, Valent, Peter, Hochhaus, Andreas, Hughes, Timothy P., van der Kuip, Heiko, Sattler, Martin, Wiktor-Jedrzejczak, Wieslaw, Richardson, Christine, Dorrance, Adrienne, Stoklosa, Tomasz, Williams, David A., Skorski, Tomasz

“…Chronic myeloid leukemia in chronic phase (CML-CP) is induced by BCR-ABL1 oncogenic tyrosine kinase. Tyrosine kinase inhibitors eliminate the bulk of CML-CP…”
Get full text

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML by Sadovnik, Irina, Hoelbl-Kovacic, Andrea, Herrmann, Harald, Eisenwort, Gregor, Cerny-Reiterer, Sabine, Warsch, Wolfgang, Hoermann, Gregor, Greiner, Georg, Blatt, Katharina, Peter, Barbara, Stefanzl, Gabriele, Berger, Daniela, Bilban, Martin, Herndlhofer, Susanne, Sill, Heinz, Sperr, Wolfgang R, Streubel, Berthold, Mannhalter, Christine, Holyoake, Tessa L, Sexl, Veronika, Valent, Peter

“…In chronic myelogenous leukemia (CML), leukemic stem cells (LSC) represent a critical target of therapy. However, little is known about markers and targets…”
Get full text

hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival by Pellicano, Francesca, Park, Laura, Hopcroft, Lisa E.M., Shah, Mansi M., Jackson, Lorna, Scott, Mary T., Clarke, Cassie J., Sinclair, Amy, Abraham, Sheela A., Hair, Alan, Helgason, G. Vignir, Aspinall-O'Dea, Mark, Bhatia, Ravi, Leone, Gustavo, Kranc, Kamil R., Whetton, Anthony D., Holyoake, Tessa L.

“…Chronic myeloid leukemia (CML) stem/progenitor cells (SPCs) express a transcriptional program characteristic of proliferation, yet can achieve and maintain…”
Get full text

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks by Pellicano, Francesca, Holyoake, Tessa L

“…The resistance of leukemic stem cells in response to targeted therapies such as tyrosine kinase inhibitors (TKIs) relies on the cooperative activity of…”
Get full text

Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1―BCR-ABL―JAK2 Complex by MIN CHEN, GALLIPOLI, Paolo, LAMBIE, Karen, NAKAMOTO, Helen, KYI MIN SAW, TURHAN, Ali, ARLINGHAUS, Ralph, PAUL, James, STOBO, Jon, BARNETT, Michael J, EAVES, Allen, EAVES, Connie J, DEGEER, Donna, HOLYOAKE, Tessa L, XIAOYAN JIANG, SLOMA, Ivan, FORREST, Donna L, CHAN, Matthew, DAMIAN LAI, JORGENSEN, Heather, RINGROSE, Ashley, HUI MI WANG

“…Imatinib mesylate (IM) induces clinical remission of chronic myeloid leukemia (CML). The Abelson helper integration site 1 (AHI-1) oncoprotein interacts with…”
Get full text